MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, FiscalAI reports.
MIRA Pharmaceuticals Trading Down 1.2%
MIRA Pharmaceuticals stock traded down $0.01 during mid-day trading on Friday, reaching $0.96. The company’s stock had a trading volume of 164,452 shares, compared to its average volume of 137,397. The firm has a market cap of $40.47 million, a price-to-earnings ratio of -0.63 and a beta of 1.48. The business has a 50 day moving average price of $1.07 and a 200-day moving average price of $1.29. MIRA Pharmaceuticals has a twelve month low of $0.90 and a twelve month high of $2.45.
Hedge Funds Weigh In On MIRA Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in MIRA Pharmaceuticals by 100.0% in the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock worth $412,000 after purchasing an additional 136,438 shares during the period. First American Bank boosted its holdings in MIRA Pharmaceuticals by 20.0% in the fourth quarter. First American Bank now owns 60,000 shares of the company’s stock worth $91,000 after purchasing an additional 10,000 shares during the period. Two Sigma Investments LP boosted its holdings in MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock worth $62,000 after purchasing an additional 25,816 shares during the period. Creative Planning acquired a new position in MIRA Pharmaceuticals in the second quarter worth $27,000. Finally, XTX Topco Ltd acquired a new position in MIRA Pharmaceuticals in the second quarter worth $26,000. Institutional investors and hedge funds own 35.16% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on MIRA Pharmaceuticals
MIRA Pharmaceuticals Company Profile
MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
Featured Articles
- Five stocks we like better than MIRA Pharmaceuticals
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for MIRA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MIRA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
